{"id":60960,"date":"2024-02-28T07:18:14","date_gmt":"2024-02-28T07:18:14","guid":{"rendered":"https:\/\/medsname.com\/trinicalm-plus\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"trinicalm-plus","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/trinicalm-plus\/","title":{"rendered":"Trinicalm Plus"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Trinicalm Plus?<\/h3>\n
\n

Trinicalm Plus<\/strong> contains a fixed-dose combination of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> from a WHO-GMP certified manufacturer (Tripada Healthcare) — a first-generation antipsychotic<\/strong> (D2<\/sub> antagonist) paired with an anticholinergic anti-Parkinson agent<\/strong> to pre-empt the extrapyramidal side effects (EPS — parkinsonism, dystonia, akathisia) that high-potency typical antipsychotics commonly cause. Used primarily in countries where typical antipsychotics remain in regular use for schizophrenia and severe anxiety\/agitation. Important warnings<\/strong>: trifluoperazine carries the FDA black box for elderly dementia mortality<\/strong>, plus high tardive dyskinesia and neuroleptic malignant syndrome risks; trihexyphenidyl has anticholinergic side effects (cognitive impairment, urinary retention, falls in elderly) and recognised abuse potential<\/strong> (sought for its euphoric \/ stimulant effect at supratherapeutic doses).<\/p>\n<\/div>\n

\nWat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde klantbeoordelingen<\/a>\n<\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n

Waarom bestellen bij MedsBase<\/h3>\n

Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen \u2014 geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor \u2014 nooit \u201cMedsBase\u201d of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Trinicalm Plus is a first-generation antipsychotic combined with an anticholinergic anti-Parkinson agent<\/strong>, prescribed and titrated over weeks for schizophrenia and other psychotic disorders, severe anxiety \/ agitation in some legacy regimens, with prophylactic coverage of antipsychotic-induced extrapyramidal symptoms (EPS)<\/strong>. It is niet<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is not approved<\/strong> for dementia-related symptoms.<\/div>\n

What Is Trinicalm Plus?<\/h2>\n

Trinicalm Plus is an oral tablet of trifluoperazine 5 mg + trihexyphenidyl 2 mg<\/strong> in fixed-dose combination, manufactured by Tripada Healthcare. The combination addresses a long-standing problem with first-generation antipsychotics: high-potency D2<\/sub> antagonists like trifluoperazine routinely cause extrapyramidal side effects (drug-induced parkinsonism, akathisia, acute dystonia) that limit tolerability and adherence. Co-prescribing an anticholinergic anti-Parkinson agent like trihexyphenidyl mitigates these motor side effects.<\/p>\n

This is a second-line approach in modern psychiatry<\/strong> — first-line is to use an atypical antipsychotic (which has lower EPS risk and does not require routine anticholinergic cover). The combination remains common in countries where typical antipsychotics are first-line for cost or availability reasons.<\/p>\n

Component Drugs<\/h2>\n

What each component does<\/h2>\n\n\n\n\n\n\n
Component<\/th>\nKlasse<\/th>\nWerkingsmechanisme<\/th>\nRole in this combination<\/th>\n<\/tr>\n<\/thead>\n
Trifluoperazine 5 mg<\/td>\nFirst-generation phenothiazine antipsychotic (high-potency)<\/td>\nTight D2<\/sub> antagonism in mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways<\/td>\nPrimary antipsychotic action; also approved for short-term treatment of severe non-psychotic anxiety not responsive to usual measures (legacy indication)<\/td>\n<\/tr>\n
Trihexyphenidyl 2 mg<\/td>\nCentrally-acting anticholinergic anti-Parkinson agent<\/td>\nM1 muscarinic antagonism in the basal ganglia, restoring acetylcholine \/ dopamine balance<\/td>\nPre-empts and treats trifluoperazine-induced parkinsonism, dystonia, and akathisia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Goedgekeurde indicaties<\/h2>\n
    \n
  • Schizophrenia and other psychotic disorders<\/strong> requiring trifluoperazine therapy with prophylactic EPS coverage<\/li>\n
  • Severe anxiety \/ agitation<\/strong> not responsive to standard treatment (legacy trifluoperazine indication; first-line modern alternatives are SSRIs and atypical antipsychotics)<\/li>\n<\/ul>\n

    Dosering<\/h2>\n\n\n\n\n\n\n\n
    Indicatie<\/th>\nTypical dose<\/th>\nMaximum<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia \/ psychosis<\/td>\n1 tablet (5\/2) BID–TID<\/td>\n3 tablets (15 mg trifluoperazine + 6 mg trihexyphenidyl) per day<\/td>\nTrifluoperazine total 5–15 mg\/day in fixed combination; higher trifluoperazine doses require separate dosing<\/td>\n<\/tr>\n
    Severe anxiety<\/td>\n1 tablet BID<\/td>\n2 tablets\/day<\/td>\nShort-term only — weeks rather than months; reassess for switch to SSRI \/ SNRI<\/td>\n<\/tr>\n
    Ouderen<\/td>\n½ tablet BID if combination is unavoidable<\/td>\n\u2014<\/td>\nHigh EPS, anticholinergic, and falls risk; black-box dementia warning<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Side Effects (by Component)<\/h2>\n

    Trifluoperazine side effects<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
    Werkingsmechanisme<\/th>\nEffecten<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
    D2<\/sub> blockade (nigrostriatal)<\/td>\nAcute dystonia (eye-rolling, torticollis, jaw clenching), parkinsonism (tremor, rigidity, bradykinesia), akathisia (inner restlessness), tardive dyskinesia (long-term involuntary movements)<\/td>\nHigh risk — the reason trihexyphenidyl is co-prescribed; tardive dyskinesia can be irreversible and develops with long-term exposure<\/td>\n<\/tr>\n
    D2<\/sub> blockade (tuberoinfundibular)<\/td>\nHyperprolactinaemia (galactorrhoea, gynaecomastia, amenorrhoea, sexual dysfunction)<\/td>\nCommon with high-potency typicals<\/td>\n<\/tr>\n
    H1<\/sub> blockade<\/td>\nSedation<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    Alpha-1 blockade<\/td>\nOrthostatic hypotension<\/td>\nLess than chlorpromazine<\/td>\n<\/tr>\n
    QT-verlenging<\/td>\nCardiac arrhythmia risk<\/td>\nBaseline ECG; caution with other QT-prolonging drugs<\/td>\n<\/tr>\n
    Anders<\/td>\nPhotosensitivity, ocular changes, jaundice<\/td>\nLong-term concerns<\/td>\n<\/tr>\n
    Zeldzaam maar ernstig<\/td>\nNeuroleptic malignant syndrome (hyperthermia, rigidity, autonomic instability, altered mental status)<\/td>\nMedical emergency<\/td>\n<\/tr>\n
    Zeldzaam<\/td>\nLowered seizure threshold<\/td>\nCaution in epilepsy<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Trihexyphenidyl side effects<\/h2>\n\n\n\n\n\n\n\n\n
    Werkingsmechanisme<\/th>\nEffecten<\/th>\nOpmerkingen<\/th>\n<\/tr>\n<\/thead>\n
    Peripheral anticholinergic<\/td>\nDry mouth, blurred vision, constipation, urinary retention<\/td>\nCommon; particularly problematic with BPH<\/td>\n<\/tr>\n
    Central anticholinergic<\/td>\nConfusion, memory impairment, cognitive dulling, agitation<\/td>\nOlder adults at greatest risk — linked to long-term cognitive decline<\/td>\n<\/tr>\n
    Anders<\/td>\nTachycardia, dizziness, falls<\/td>\nFalls risk in elderly<\/td>\n<\/tr>\n
    Important<\/td>\nAbuse potential<\/strong><\/td>\nTrihexyphenidyl is sought at supratherapeutic doses for euphoric \/ stimulant \/ hallucinogenic effects; some jurisdictions have introduced controls. Patients with substance use history need monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Geneesmiddelinteracties<\/h2>\n

    QT-verlenging<\/strong>: avoid combination with other QT-prolonging drugs — ziprasidone, citalopram (high dose), methadone, ondansetron, fluoroquinolones.<\/p>\n

    Anticholinergic stacking<\/strong>: trihexyphenidyl already pushes anticholinergic burden — combine cautiously with TCAs, paroxetine, antihistamines, oxybutynin, hyoscyamine; in older adults this can produce confusion, falls, and urinary retention.<\/p>\n

    CNS depression<\/strong>: alcohol, benzodiazepines, opioids — additive sedation.<\/p>\n

    Antihypertensiva<\/strong>: additive orthostasis.<\/p>\n

    Levodopa antagonism<\/strong>: trifluoperazine D2<\/sub> blockade reduces levodopa effect — problematic in Parkinson’s disease.<\/p>\n

    Why Modern Practice Often Avoids This Combination<\/h2>\n

    Where atypical antipsychotics are available and affordable, modern practice generally avoids first-generation antipsychotics + routine anticholinergic cover<\/strong> because:<\/p>\n